Momenta Pharmaceuticals (MNTA) PT Raised to $36 at Goldman Sachs, Following Trial Data Release Yesterday
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh raised the price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $36.00 (from $29.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Transurban Group (TCL:AU) (TRAUF) PT Lowered to AUD13.50 at Macquarie
- Harley-Davidson (HOG) PT Raised to $33 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
